10-K: American Cannabis Company Reports Significant Revenue Drop in 2023 Amidst Market Downturn

American Cannabis Company experienced a substantial decrease in revenue in 2023, primarily due to a decline in product and equipment sales, alongside a general market downturn in the cannabis sector.

Summary

• American Cannabis Company, Inc. reported a total revenue of $2,476,185 for the year ended December 31, 2023, a significant decrease from $18,808,545 in 2022.
• The company's product and equipment sales saw a major drop of $16,515,186, attributed to the termination of a key contract.
• Cannabis product sales also decreased slightly to $756,905 in 2023 from $793,331 in 2022, reflecting a general market decline in Colorado.
• Consulting service revenues increased to $695,089 in 2023 from $475,837 in 2022, due to new states legalizing cannabis and ongoing projects.
• The company's net loss for 2023 was $3,660,416, compared to a net loss of $633,192 in 2022.
• Operating expenses increased to $4,893,035 in 2023 from $3,142,870 in 2022, primarily due to goodwill impairment and increased stock-based compensation.
• The company's gross profit decreased to $1,041,882 in 2023 from $2,537,214 in 2022.
• As of December 31, 2023, the company had cash and cash equivalents of $21,085 and accounts receivable of $234,330.
• The company issued 79,250,000 common shares during the year ended December 31, 2023.

Sentiment

Score: 3

Explanation: The document indicates a significant downturn in the company's financial performance, with substantial revenue decline, increased losses, and internal control issues. While there are some positive aspects, the overall tone is negative from an investment perspective.

Positives

• Consulting service revenues increased by $219,252, indicating growth in this segment.
• The company's consulting services gross profit was $580,004 for the year ended December 31, 2023.
• The company has a low fixed overhead cost structure.
• The company has the ability to issue stock to compensate employees and management.

Negatives

• Total revenue decreased by $16,332,360 year-over-year, primarily due to a significant drop in product and equipment sales.
• The company experienced a net loss of $3,660,416 in 2023, a substantial increase from the $633,192 loss in 2022.
• The company's goodwill was fully impaired, resulting in a $1,332,113 expense.
• Stock-based compensation expenses increased significantly to $1,735,021 in 2023.
• The company's cash and cash equivalents were $21,085 as of December 31, 2023.
• The company's gross profit decreased to $1,041,882 in 2023 from $2,537,214 in 2022.
• The company's cannabis product sales decreased slightly to $756,905 in 2023 from $793,331 in 2022.

Risks

• The company's reliance on a small number of customers poses a risk to revenue stability.
• The company's operations are subject to the risks associated with the cannabis industry, including regulatory changes and federal prohibition.
• The company has a history of operating losses and negative cash flows, raising concerns about its ability to continue as a going concern.
• The company's internal controls over financial reporting were deemed ineffective due to material weaknesses.
• The company may need to raise short-term capital to mitigate delays in receiving accounts receivable payments.
• The company is subject to the limitations of Internal Revenue Code (IRC) Section 280E, which limits deductible expenses.

Future Outlook

Management believes it will need to raise short-term capital to mitigate any periodic delays in receipt of accounts receivable and that this strategy will adequately provide the necessary liquidity and capital resources to fund operational, general, and administrative expenses for at least the next 12 months.

Management Comments

• Management believes that it will need to raise short-term capital to mitigate any periodic delays in receipt of accounts receivable.
• Management believes this strategy will adequately provide the necessary liquidity and capital resources to fund our operational general, and administrative expenses for at least the next 12 months.

Industry Context

The company's performance reflects the broader challenges faced by the cannabis industry, including market saturation and regulatory uncertainty. The decline in Colorado's cannabis sales by 16% in 2023 highlights the competitive and evolving nature of the market.

Comparison to Industry Standards

• The company's significant revenue decline contrasts with some larger, more established cannabis companies that have shown more resilience in the face of market challenges.
• The company's reliance on a few key customers is a deviation from industry best practices, where diversification of revenue streams is generally preferred.
• The company's goodwill impairment suggests that the acquisition of Naturaleaf may not have met initial expectations, which is a common risk in the cannabis industry due to its volatility.
• The company's internal control weaknesses are a concern, as robust controls are essential for financial reporting in a regulated industry.

Management Changes

Corporate Governance

Related Party Transactions

• On November 22, 2022, the Company issued a promissory note to Ellis Smith in exchange for $150,000.

Stakeholder Impact

• Shareholders are negatively impacted by the significant net loss and the decrease in share price.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may experience changes in product offerings or service quality due to the company's financial challenges.
• Creditors may face increased risk due to the company's financial instability.

Next Steps

• The company intends to implement specific remediation initiatives to address material weaknesses in internal controls.
• The company plans to evaluate system and manual controls, identify specific weaknesses, and implement a comprehensive system of internal controls.
• The company intends to allocate resources to perform a risk assessment and map processes to control objectives.

Key Dates

Keywords

cannabis, revenue, consulting, equipment, dispensary, cultivation, financial results, net loss, goodwill impairment, stock compensation, internal controls, operating expenses